JP7211952B2 - ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 - Google Patents

ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 Download PDF

Info

Publication number
JP7211952B2
JP7211952B2 JP2019536507A JP2019536507A JP7211952B2 JP 7211952 B2 JP7211952 B2 JP 7211952B2 JP 2019536507 A JP2019536507 A JP 2019536507A JP 2019536507 A JP2019536507 A JP 2019536507A JP 7211952 B2 JP7211952 B2 JP 7211952B2
Authority
JP
Japan
Prior art keywords
seq
netrin
sequence
nos
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019536507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503359A5 (cg-RX-API-DMAC7.html
JP2020503359A (ja
Inventor
バンジャマン・デュカルージュ
ダヴィド・ゴルドシュネデール
アンナ・マリア・リタ・レデイヴィッド
バンジャマン・ジベール
パトリック・メーラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of JP2020503359A publication Critical patent/JP2020503359A/ja
Publication of JP2020503359A5 publication Critical patent/JP2020503359A5/ja
Priority to JP2022151769A priority Critical patent/JP2022176250A/ja
Application granted granted Critical
Publication of JP7211952B2 publication Critical patent/JP7211952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019536507A 2017-01-05 2018-01-05 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 Active JP7211952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022151769A JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305014 2017-01-05
EP17305014.7 2017-01-05
PCT/EP2018/050289 WO2018127570A1 (en) 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022151769A Division JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Publications (3)

Publication Number Publication Date
JP2020503359A JP2020503359A (ja) 2020-01-30
JP2020503359A5 JP2020503359A5 (cg-RX-API-DMAC7.html) 2022-05-20
JP7211952B2 true JP7211952B2 (ja) 2023-01-24

Family

ID=57838304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536507A Active JP7211952B2 (ja) 2017-01-05 2018-01-05 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療
JP2022151769A Pending JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022151769A Pending JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Country Status (10)

Country Link
US (2) US12162932B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565837B1 (cg-RX-API-DMAC7.html)
JP (2) JP7211952B2 (cg-RX-API-DMAC7.html)
KR (1) KR102679324B1 (cg-RX-API-DMAC7.html)
CN (1) CN110291105B (cg-RX-API-DMAC7.html)
AU (1) AU2018205730B2 (cg-RX-API-DMAC7.html)
CA (1) CA3048347A1 (cg-RX-API-DMAC7.html)
EA (1) EA039433B1 (cg-RX-API-DMAC7.html)
IL (1) IL267775B1 (cg-RX-API-DMAC7.html)
WO (1) WO2018127570A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022176250A (ja) * 2017-01-05 2022-11-25 ネトリス ファーマ ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024001308A (es) * 2021-07-27 2024-05-23 Netris Pharma Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones.
CA3246346A1 (en) * 2022-03-29 2023-10-05 Netris Pharma NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR
WO2024095723A1 (ja) 2022-11-02 2024-05-10 シチズン・システムズ株式会社 プリンタ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104360A1 (en) 2014-01-10 2015-07-16 Netris Pharma Novel anti-netrin-1 antibody
WO2016197204A1 (en) 2015-06-11 2016-12-15 Bionomics Limited Pharmaceutical combination and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2601352T3 (es) 2006-02-28 2017-02-14 Centre National De La Recherche Scientifique (Cnrs) Cribado para compuestos anti-cáncer usando actividad de netrina-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2609430A1 (en) 2010-08-26 2013-07-03 F.Hoffmann-La Roche Ag Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN104083762A (zh) * 2014-06-27 2014-10-08 中国科学院生物物理研究所 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104360A1 (en) 2014-01-10 2015-07-16 Netris Pharma Novel anti-netrin-1 antibody
WO2016197204A1 (en) 2015-06-11 2016-12-15 Bionomics Limited Pharmaceutical combination and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022176250A (ja) * 2017-01-05 2022-11-25 ネトリス ファーマ ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Also Published As

Publication number Publication date
KR20190101991A (ko) 2019-09-02
EP3565837C0 (en) 2024-04-10
EP3565837B1 (en) 2024-04-10
CA3048347A1 (en) 2018-07-12
JP2022176250A (ja) 2022-11-25
AU2018205730B2 (en) 2024-05-30
EA201991302A1 (ru) 2019-11-29
WO2018127570A1 (en) 2018-07-12
IL267775B1 (en) 2026-06-01
IL267775A (en) 2019-09-26
EP3565837A1 (en) 2019-11-13
US20190315852A1 (en) 2019-10-17
AU2018205730A1 (en) 2019-07-11
JP2020503359A (ja) 2020-01-30
US12162932B2 (en) 2024-12-10
CN110291105A (zh) 2019-09-27
EA039433B1 (ru) 2022-01-27
CN110291105B (zh) 2024-03-01
KR102679324B1 (ko) 2024-06-28
US20250002572A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
US12187798B2 (en) LAG-3 binding members
JP2023126946A (ja) 抗lag-3抗体、pd-1経路阻害剤および免疫療法剤の組み合わせを含む組成物
US20210115123A1 (en) Trispecific inhibitors for cancer treatment
KR102777244B1 (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
JP7284557B2 (ja) 医薬組成物
JP7754506B2 (ja) ポリオウイルス受容体(pvr)に対する抗体およびその使用
US20250002572A1 (en) Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
CA3043656A1 (en) Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
EP3091998A1 (en) Humanized or chimeric cd3 antibodies
JP2020511481A (ja) 固形及び血液癌の治療のための併用療法
JP2023554422A (ja) がんの治療のための多重特異性抗体
TWI790193B (zh) 調控免疫反應之方法及抗體
CA3155172A1 (en) Combination of anti-garp antibody and immunomodulator
TW202528358A (zh) 利用結合至epcam及cd137之藥劑與pd-1軸結合拮抗劑組合的治療方法
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
CN118339183A (zh) 组合中针对pd-l1和cd137的多特异性结合剂
EA051733B1 (ru) Композиции, содержащие комбинацию анти-lag-3 антитела, ингибитора сигнального пути pd-1 и иммунотерапевтического средства

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220214

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220922

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221017

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221124

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230112

R150 Certificate of patent or registration of utility model

Ref document number: 7211952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250